Westermann, Jörg <br/><br/>
Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)   
 - 667-75 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1537-4513 
<br/><br/><label>Standard No.: </label>10.1097/CJI.0b013e3181a950e5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>B7-1 Antigen--immunology<br/>B7-2 Antigen--immunology<br/>Cancer Vaccines--immunology<br/>Carcinoma, Renal Cell--drug therapy<br/>Female<br/>Fluorouracil--administration & dosage<br/>Granulocyte-Macrophage Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Interferon-alpha--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>T-Lymphocytes--immunology